LeadArtis

Immuno-oncology (IO) is aimed at destroying cancer by stimulating the patient’s immune system delivering lasting responses and cure.

The global IO market will reach $119B by 2021 (14% CAGR). Our Bispecific Hexavalent Trimerbody (BHTs) provides remarkable tumor killing by infiltrating T lymphocytes. Join the development of a first-in class BHT with clinically validated mechanisms of action for treatment of advanced lung and colon tumors.

The objective is enhancing efficacy and reducing adverse effects. Financial needs for 18 months: 1 M€ leveraged with 0.5 M€ non-dilutive public financing for comprehensive in vivo PoC studies, initial pre-GMP manufacturing and early preclinical safety studies.

At this point will be licensed out to a partner.